Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Robert Davis
Pharma
BMS, Merck, Amgen and more face near-term generic woes: Leerink
As patent expirations near for many of the world’s top drugmakers, companies will need to be diligent about M&A, according to a new Leerink report.
Fraiser Kansteiner
Nov 13, 2024 10:57am
The top 10 best-paid CEOs in Big Pharma in 2023
Jun 17, 2024 3:00am
Merck CEO Robert Davis receives 9% pay hike to $20.3M
Apr 12, 2024 10:27am
CEOs from BMS, J&J and Merck defend high drug costs to senators
Feb 8, 2024 3:05pm
Sanders' report pings BMS, Merck, J&J over drug pricing in US
Feb 6, 2024 4:02pm
Even after Prometheus, Acceleron deals, Merck primed for M&A
Feb 1, 2024 11:01am
